IMR Press / EJGO / Volume 38 / Issue 1 / DOI: 10.12892/ejgo3322.2017

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Short-term curative effect and safety of bevacizumab combined with chemotherapy for treating recurrent and metastatic cervical cancer
Show Less
1 Department of Gynecologic Oncology, Cancer Hospital of Zhengzhou University (Henan Tumor Hospital), Zhengzhou, China
Eur. J. Gynaecol. Oncol. 2017, 38(1), 76–79; https://doi.org/10.12892/ejgo3322.2017
Published: 10 February 2017
Abstract

Objective: To observe bevacizumab plus chemotherapy curative effect and safety for recurrent and metastatic cervical cancer. Materials and Methods: Retrospective analysis of 30 recurrent and metastatic cervical cancer cases. The experimental group received bevacizumab plus paclitaxel-, docetaxel-, and platinum-based chemotherapy. The control group received only chemotherapy. Curative effects were recorded after at least two treatment cycles; adverse reactions were recorded with every cycle. Results: Experimental group patients were treated for an average 2.6 cycles. Compared to the control group, the experimental group effective rate (26.7%) was similar, disease control rate (73.7%) was significantly higher, and median survival time was three months longer. Bevacizumab-associated adverse reactions were bleeding, hypertension, and thrombosis/embolism; most were level 1 and 2 reactions. Adverse reactions in the two groups were not statistically different. Conclusions: The bevacizumab plus chemotherapy disease control rate for recurrent and metastatic cervical cancer is comparatively high, prolonging median survival; bevacizumab-associated adverse reactions are mild and tolerable.
Keywords
Cervical neoplasms
Bevacizumab
Drug therapy
Targeted therapy
Drug toxicity
Share
Back to top